Rufinamide oral suspension approved for seizures

The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome.

The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy.

Lennox-Gastaut syndrome usually begins before 4 years of age as a result of brain malformations, severe head injury, perinatal asphyxia, central nervous system infection, or inherited degenerative or metabolic disorders. Patients may experience frequent seizures. One-third of cases present with no perceivable causes.

Children with LGS display developmental delays and impaired intellectual function, information processing, and behavior.

Rufinamide is approved for children 4 years of age and older and adults. The new oral suspension benefits patients who prefer a liquid or who find tablets difficult to swallow.

Related Videos
Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California | Image provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Thomas R. Young, MD | Image Credit: Author provided
J. Thomas Megerian, MD, PhD, FAAP | Author provided
© 2023 MJH Life Sciences

All rights reserved.